Pluristem Therapeutics Inc (PSTI)

[FDApproved]

We believe that we have sufficient cash to fund our operations for at least the next twelve months. On June 30, 2022, we had a working capital surplus of $50,918,000

During the year ended June 30, 2022, we did not sell of our any common shares under the ATM Agreement.

We expect to generate revenues, from the sale of licenses to use our technology or products, but in the short and medium terms will unlikely exceed our costs of operations.

As of June 30, 2022, the Company’s cash position (cash and cash equivalents, short-term bank deposits, long-term bank deposits, restricted cash and restricted bank deposits) totaled $56,657. The Company plans to continue to finance its operations from its current resources, by entering into licensing or other commercial agreements,

Cash and cash equivalents

Cash equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less at the date acquired.

News Coming !!!

For Mr. Yanay and Ms. Franco-Yehuda, we have accrued, but have not yet paid, bonuses during Fiscal Year 2022 of $64,000 and $44,000 respectively, for certain target bonuses as a result of the achievement of certain milestones that were defined by the Compensation Committee. We expect to pay such bonuses during October 2022.